Journal
JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM
Volume 104, Issue 12, Pages 6129-6138Publisher
ENDOCRINE SOC
DOI: 10.1210/jc.2019-01204
Keywords
-
Categories
Funding
- Internationalization Foundation
- Institute for ClinicalMedicine
- University of Copenhagen
- Danish Cancer Society
- Arvid Nilssons Foundation
Ask authors/readers for more resources
Introduction: Diagnosis and pathological classification of insulinomas are challenging. Aim: To characterize localization of tumors, surgery outcomes, and histopathology in patients with insulinoma. Methods: Patients with surgically resected sporadic insulinoma were included. Results: Eighty patients were included. Seven had a malignant tumor. A total of 312 diagnostic examinations were performed: endoscopic ultrasonography (EUS; n = 59; sensitivity, 70%), MRI (n=33; sensitivity, 58%), CT (n=55; sensitivity, 47%), transabdominal ultrasonography (US; n=45; sensitivity, 40%), somatostatin receptor imaging (n = 17; sensitivity, 29%), F-18-fluorodeoxyglucose positron emission tomography/CT (n = 1; negative), percutaneous transhepatic venous sampling (n = 10; sensitivity, 90%), arterial stimulation venous sampling (n = 20; sensitivity, 65%), and intraoperative US (n = 72; sensitivity, 89%). Fourteen tumors could not be visualized. Invasive methods were used in 7 of these 14 patients and localized the tumor in all cases. Median tumor size was 15 mm(range, 7 to 80 mm). Tumors with malignant vs benign behavior showed less staining for insulin (3 of 7 vs 66 of 73; P = 0.015) and for proinsulin (3 of 6 vs 58 of 59; P < 0.001). Staining for glucagon was seen in 2 of 6 malignant tumors and in no benign tumors (P < 0.001). Forty-three insulinomas stained negative for somatostatin receptor subtype 2a. Conclusion: Localization of insulinomas requires many different diagnostic procedures. Most tumors can be localized by conventional imaging, including EUS. For nonvisible tumors, invasive methods may be a useful diagnostic tool. Malignant tumors showed reduced staining for insulin and proinsulin and increased staining for glucagon.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available